Blakely CM et.al pointed out that tumor genomic complexity increased with the prolongation of EGFR-TKIs treatment, a change that, sometimes along with the co-mutation of other genes, can promote tumor development or limits EGFR inhibitor response [21]. The gene discussed is EGFR; the disease is neoplasm.